...
首页> 外文期刊>Pediatric Research >Surfactant Composition and Function in a Primate Model of Infant Chronic Lung Disease: Effects of Inhaled Nitric Oxide
【24h】

Surfactant Composition and Function in a Primate Model of Infant Chronic Lung Disease: Effects of Inhaled Nitric Oxide

机译:婴儿慢性肺疾病灵长类动物模型中的表面活性剂组成和功能:吸入一氧化氮的影响

获取原文
           

摘要

Bronchopulmonary dysplasia, or chronic lung disease (CLD), of premature infants involves injury from hyperoxia and mechanical ventilation to an immature lung. We examined surfactant and nitric oxide (NO), which are developmentally deficient in premature infants, in the baboon model of developing CLD. Fetuses were delivered at 125 d gestation and were managed for 14 d with ventilation and oxygen prn without (controls) or with inhaled NO at 5 ppm. Compared with term infants, premature control infants had reduced maximal lung volume, decreased tissue content of surfactant proteins SP-A, -B, and -C, abnormal lavage surfactant as assessed by pulsating bubble surfactometer, and a low concentration of SP-B/phospholipid. NO treatment significantly increased maximal lung volume and tissue SP-A and SP-C, reduced recovery of lavage surfactant by 33%, decreased the total protein:phospholipid ratio of surfactant by 50%, and had no effect on phospholipid composition or SP content except for SP-C (50%). In both treatment groups, levels of SP-B and SP-C in surfactant were negatively correlated with STmin, with a 5-fold greater SP efficiency for NO versus control animals. By contrast, lung volume and compliance were not correlated with surfactant function. We conclude that surfactant is often dysfunctional in developing CLD secondary to SP-B deficiency. NO treatment improves the apparent ability of hydrophobic SP to promote low surface tension, perhaps secondary to less protein inactivation of surfactant, and improves lung volume by a process unrelated to surfactant function.Abbreviations: BAL, bronchoalveolar lavage; BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; PL, phospholipid; SP, surfactant protein; STmin, minimum surface tension
机译:早产儿的支气管肺发育不良或慢性肺部疾病(CLD)涉及高氧和未成熟肺部机械通气的伤害。我们在发展CLD的狒狒模型中检查了早产儿发育不足的表面活性剂和一氧化氮(NO)。胎儿在​​妊娠125 d时分娩,并在不使用(对照)或吸入5 ppm NO的情况下进行通气和氧气治疗14 d。与足月婴儿相比,早产对照婴儿的最大肺活量减少,表面活性剂蛋白SP-A,-B和-C的组织含量降低,通过脉动气泡表面张力计评估的灌洗表面活性剂含量异常,并且SP-B /磷脂。 NO处理显着增加了最大肺体积和组织SP-A和SP-C,使灌洗表面活性剂的回收率降低了33 %,表面活性剂的总蛋白:磷脂比例降低了50 %,并且对磷脂成分或SP没有影响SP-C除外(50 %)。在两个治疗组中,表面活性剂中SP-B和SP-C的含量均与STmin呈负相关,NO的SP效率比对照动物高5倍。相反,肺活量和顺应性与表面活性剂功能无关。我们得出的结论是,表面活性剂通常在继发于SP-B缺乏症的CLD中功能失调。 NO处理可改善疏水性SP促进低表面张力的表观能力,这可能是由于表面活性剂的蛋白质失活较少所致,并通过与表面活性剂功能无关的过程改善了肺体积。BAL,支气管肺泡灌洗; BPD,支气管肺发育不良; CLD,慢性肺病; PL,磷脂; SP,表面活性剂蛋白; STmin,最小表面张力

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号